DEFA14A: Analysts Back Alcon-STAAR Merger, Cite Standalone Risks

STAAR Surgical highlights independent industry analyst support for its merger with Alcon, emphasizing the premium cash value and significant downside risks if the deal fails.

Summary

• STAAR Surgical is urging stockholders to vote FOR the Alcon merger, which offers $28 per share in cash.
• Independent industry analysts recognize the compelling, certain, premium cash value provided by the Alcon merger and the significant downside risks STAAR faces as a standalone company.
• Prior to the Alcon transaction, the median sell-side analyst price target for STAAR was only $19.00 per share.
• The Alcon offer represents approximately a 59% premium to STAAR's 90-day Volume Weighted Average Price (VWAP) and a 51% premium to the closing price of STAAR common stock on August 4, 2025.
• The transaction represents a total equity value of approximately $1.5 billion, or 4.7x FY26 sales.
• STAAR's China business experienced a major deterioration, with Q2 2025 Chinese revenue at ~$5.3M, a 92% year-over-year decrease from $63.3M in Q2 2024, driven by excess channel inventory and a challenging macro environment.
• Analysts believe a competing proposal for STAAR is unlikely, noting the multiple paid and the company's current challenges, and that STAAR has not received any other acquisition or merger proposal for more than 10 years.
• A virtual Special Meeting of Stockholders is scheduled for October 23, 2025, at 8:30 a.m. (Pacific Time) to vote on the Alcon merger.
• The STAAR Board of Directors unanimously recommends that all STAAR stockholders vote FOR the merger proposal on the WHITE proxy card.

Sentiment

Score: 8

Explanation: The filing strongly advocates for the merger, presenting it as the optimal outcome for stockholders given STAAR's significant operational challenges and the substantial premium offered. The tone is urgent and persuasive, highlighting the benefits of the deal and the risks of rejection.

Positives

• The Alcon merger provides a compelling, certain, premium cash value of $28 per share to stockholders.
• The $28/share offer represents an attractive 30% premium (3.8x) to the mean 2025E EV/Sales multiple of the small cap Med-Tech comp group (2.9x) applied to 2026E revenue of $335M.
• The offer is a substantial 59% premium to STAAR's 90-day Volume Weighted Average Price (VWAP) and a 51% premium to the closing price on August 4, 2025.
• The transaction values STAAR at approximately $1.5 billion (4.7x FY26 sales), which analysts consider sufficiently fair and rich enough to limit the risk of an over-the-top counteroffer.
• Analysts do not expect a higher rival bid, suggesting the current offer is robust and unlikely to be surpassed.
• The merger provides an exit strategy from sustained challenges, particularly the significant deterioration in the Chinese market.

Negatives

• STAAR faces sustained challenges as a standalone company, particularly due to dynamics in the broader Chinese economy.
• Q2 2025 Chinese revenue was approximately $5.3 million, representing a material 92% year-over-year decrease from $63.3 million in Q2 2024.
• The China business experienced a major deterioration in 4Q24 results and initial 2025 outlook, driven by excess channel inventory and a challenging macro environment.
• STAAR shares are down 24% year-to-date due to weak earnings impacted by softer China demand.
• There is limited visibility into moving past the macroeconomic challenges related to China if the company remains standalone.
• If the Alcon merger is not completed, the stock price is expected to respond negatively due to the fading acquisition premium and ongoing operational challenges.

Risks

• The occurrence of any event, change, or other circumstances that could give rise to the termination of the Alcon merger agreement or cause the consummation of the proposed transaction to be delayed or fail to occur.
• Failure to obtain approval of the proposed transaction from STAAR's stockholders.
• Failure to obtain certain required regulatory approvals or to satisfy any of the other closing conditions to the completion of the proposed transaction within expected timeframes or at all.
• Risks related to disruption of management's attention from STAAR's ongoing business operations due to the proposed transaction.
• The effect of the announcement of the proposed transaction on STAAR's ability to retain and hire key personnel and maintain relationships with its customers, suppliers, and others.
• The ability of STAAR to meet expectations regarding the timing and completion of the transaction.
• The outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction.
• The possibility that STAAR's stock price may decline significantly if the proposed transaction is not consummated, as the current acquisition premium would fade.
• Sustained challenges as a standalone company, particularly in the Chinese economy, with limited visibility for recovery.
• No guarantee that Alcon, the most logical buyer, would participate in any future process if the current merger agreement is not approved.
• The unlikelihood of a competing proposal, as STAAR has not received any other acquisition or merger proposal for more than 10 years.

Future Outlook

STAAR expects inventory levels in China to align by Q3 2025 with in-market procedure volume, contingent on global macroeconomic conditions improving, though analysts express uncertainty about this. The Alcon transaction is expected to close in the next twelve months if approved by stockholders and regulatory bodies.

Management Comments

• "Prior to the Alcon transaction, the median sell-side analyst price target for STAAR was only $19.00 per share. It is clear that industry analysts recognize the downside risks facing STAAR and STAAR stockholders, and the compelling, certain, premium $28 per share cash value provided by the Alcon merger." Stephen Farrell, CEO of STAAR.
• "If the Alcon merger agreement is not approved on October 23, it could be a deterrent to any future buyers and there is no guarantee that Alcon, who is the most logical buyer of this asset, would participate in any future process." Stephen Farrell, CEO of STAAR.
• "We urge STAARs stockholders to vote FOR the Alcon merger today." Stephen Farrell, CEO of STAAR.
• The STAAR Board of Directors unanimously recommends that all STAAR stockholders vote FOR the merger proposal on the WHITE proxy card TODAY.

Industry Context

The filing highlights significant challenges in the broader Chinese economy impacting medical device companies like STAAR, suggesting a difficult operating environment in that region. The proposed merger with Alcon, a global leader, indicates potential consolidation within the ophthalmic surgery market, driven by the need for scale or an exit strategy for companies facing substantial headwinds. The premium paid by Alcon suggests a strategic valuation despite STAAR's recent operational struggles.

Comparison to Industry Standards

• The $28/share offer represents a 30% premium (3.8x) to the mean 2025E EV/Sales multiple of the small cap Med-Tech comp group (2.9x), indicating the offer is above industry averages for similar companies.
• The proposed exit multiple of ~5.9x (based on 2026E revenue of $335M) is considered 'sufficiently fair and rich enough' by Mizuho, limiting the risk of a counteroffer compared to typical acquisition multiples.
• The takeover price represents 6x estimated 2025 sales, which Sidoti views as a strong valuation given STAAR's recent performance.

Legal Proceedings

• The filing mentions the risk of 'any legal proceedings that may be instituted against STAAR related to the proposed transaction', but no specific current proceedings are detailed.

Stakeholder Impact

• Shareholders: Will receive a premium cash value for their shares, mitigating risks associated with STAAR's standalone operational challenges. Failure to approve the merger could lead to a significant decline in stock price.
• Employees: The proposed transaction may cause disruption to management's attention and could affect the ability to retain and hire key personnel.
• Customers and Suppliers: The announcement of the proposed transaction may impact relationships with customers and suppliers.

Next Steps

• Stockholders are urged to vote FOR the Alcon merger on the WHITE proxy card.
• A virtual Special Meeting of Stockholders will be held on October 23, 2025, at 8:30 a.m. (Pacific Time) to vote on the merger proposal.
• The merger will only be approved if holders of a majority of STAAR's outstanding common stock vote FOR it.
• The Alcon transaction is expected to close in the next twelve months, subject to stockholder and regulatory approvals.

Key Dates

Recommendation

The filing strongly indicates that the Alcon merger offers a significant premium and a clear exit strategy for STAAR stockholders, especially given the company's severe operational challenges in the key China market and the lack of other acquisition interest for over a decade. Rejecting the merger carries substantial downside risk, including a likely stock price decline and no guarantee of future offers. Therefore, a seasoned investor would strongly recommend voting for the merger to secure the premium cash value.

Keywords

STAAR Surgical, Alcon, Merger, Acquisition, Proxy Solicitation, Stockholder Vote, ICL, Implantable Collamer Lenses, Vision Correction, Ophthalmology, China Market, Med-Tech, Premium Offer, Downside Risk